PCOS Officially Renamed PMOS as Medical Community Updates Diagnostic Standards

Polycystic Ovary Syndrome, long known as PCOS, has been officially renamed Polycystic Metabolic and Ovarian Syndrome, or PMOS, as part of an update to diagnostic standards in 2026.

Health experts say the new name more accurately captures the condition's metabolic components, which include insulin resistance, elevated androgen levels, and increased risk of type 2 diabetes. The previous name focused primarily on the ovarian cysts that can appear with the condition, which are not present in all patients and are not the defining feature of the disorder.

The renaming follows years of advocacy from patients and clinicians who argued that PCOS was poorly understood partly because of its misleading name. Many women with the condition do not have visible cysts, leading to delayed or missed diagnoses.

PMOS affects an estimated 8 to 13 percent of women of reproductive age worldwide, making it one of the most common hormonal disorders. Symptoms include irregular periods, excess hair growth, acne, and difficulty conceiving.

The updated terminology is expected to appear in medical education materials, clinical guidelines, and patient resources over the coming months. Advocacy groups have welcomed the change, saying it will help patients better understand their diagnosis and communicate with healthcare providers.

Researchers say the shift also opens the door to more targeted treatment approaches that address the metabolic aspects of the condition alongside reproductive health.